Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling

Experimental and Therapeutic Medicine

Volumn 2, Issue 1, 2011, Pages 47-56

  Kato, Yoichiro ^a,b   Zembutsu, Hitoshi ^a   Takata, Ryo ^b   Miya, Fuyuki ^c   Tsunoda, Tatsuhiko ^c   Obara, Wataru ^b   Fujioka, Tomoaki ^b   Nakamura, Yusuke ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c RIKEN   (Japan)

Author keywords

Bladder cancer; Carboplatin; Gemcitabine; Gene expression profile; Microarray; Neoadjuvant chemotherapy; Prediction

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTION; SCORING SYSTEM;

EID: 78751611811     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.166     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer JClin 55: 74-108, 2005.
2. Sternberg CN: The treatment of advanced bladder cancer. Ann Oncol 6: 113-126, 1995.
3. Fagg SL, Dawson-Edwards P, Hughes MA, Latief TN, Rolfe EB and Fielding JW: Cis-diamminedichloroplatinum (DDP) as initial treatment of invasive bladder cancer. Br JUrol 56: 296-300, 1984.
4. Raghavan D, Pearson B, Coorey G, et al: Intravenous cis-platinum for invasive bladder cancer. Safety and feasibility of a new approach. Med JAust 140: 276-278, 1984.
5. Advanced Bladder Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361: 1927-1934, 2003.
6. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl JMed 349: 859-866, 2003.
7. Von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. JClin Oncol 23: 4602-4608, 2005.
8. Cam K, Yildirim A, Ozveri H, Turkeri L and Akdas A: The efficacy of neoadjuvant chemotherapy in invasive bladder cancer. Int Urol Nephrol 33: 49-52, 2002.
9. Dogliotti L, Carteni G, Siena S, et al: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52: 134-141, 2007.
10. Bamias A, Moulopoulos LA, Koutras A, et al: The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase IIstudy of the Hellenic Cooperative Oncology Group. Cancer 106: 297-303, 2006.
11. Nikolova DN, Zembutsu H, Sechanov T, et al: Genome-wide gene expression profiles of thyroid carcinoma: identification of molecular targets for treatment of thyroid carcinoma. Oncol Rep 20: 105-121, 2008.
12. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999.
13. Takata R, Katagiri T, Kanehira M, et al: Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11: 2625-2636, 2005.
14. Yamanaka Y, Tamari M, Nakahata T and Nakamura Y: Gene expression profiles of human small airway epithelial cells treated with low doses of 14- and 16-membered macrolides. Biochem Biophys Res Commun 287: 198-203, 2001.
15. Takata R, Katagiri T, Kanehira M, et al: Validation study of the prediction system for clinical response of M-VACneoadjuvant chemotherapy. Cancer Sci 98: 113-117, 2007.
16. Zehorai E, Yao Z, Plotnikov A and Seger R: The subcellular localization of MEK and ERK - a novel nuclear translocation signal (NTS) paves a way to the nucleus. Mol Cell Endocrinol 314: 213-220, 2009.
17. Matsumoto K, Nagahara T, Okano J and Murawaki Y: The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep 20: 863-872, 2008.
18. Yokoi K and Fidler IJ: Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 10: 2299-2306, 2004.
19. Iwao-Koizumi K, Matoba R, Ueno N, et al: Prediction of docetaxel response in human breast cancer by gene expression profiling. JClin Oncol 23: 422-431, 2005.
20. Esrig D, Elmajian D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl JMed 331: 1259-1264, 1994.
21. Cote RJ, Dunn MD, Chatterjee SJ, et al: Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58: 1090-1094, 1998.
22. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW and Pauwels RP: MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer 88: 2598-2605, 2000.
23. Stein JP, Ginsberg DA, Grossfeld GD, et al: Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. JNatl Cancer Inst 90: 1072-1079, 1998.
24. Inoue K, Slaton JW, Karashima T, et al: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 6: 4866-4873, 2000.
25. Rho SB, Woo JS, Chun T and Park SY: Cysteine-rich 61 (CYR61) inhibits cisplatin-induced apoptosis in ovarian carcinoma cells. Biotechnol Lett 31: 23-28, 2009.
26. Gery S, Xie D, Yin D, et al: Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 11: 7243-7254, 2005.
27. Dao D, Frank D, Qian N, et al: IMPT1, an imprinted gene similar to polyspecific transporter and multi-drug resistance genes. Hum Mol Genet 7: 597-608, 1998.
28. Okabe M, Szakacs G, Reimers MA, et al: Profiling SLCO and SLC22 genes in the NCI-60 cancer cell line to identify drug uptake transporters. Mol Cancer Ther 7: 3081-3091, 2008.
29. Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl JMed 350: 1828-1837, 2004.
30. Ma XJ, Wang Z, Ryan PD, et al: Atwo-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616, 2004.